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Abstract
Background: Preterm prelabour rupture of the membranes (PPROM) is an important clinical 
problem and a dilemma for the gynaecologist. On the one hand, awaiting spontaneous labour 
increases the probability of infectious disease for both mother and child, whereas on the other 
hand induction of labour leads to preterm birth with an increase in neonatal morbidity (e.g., 
respiratory distress syndrome (RDS)) and a possible rise in the number of instrumental deliveries.
Methods/Design: We aim to determine the effectiveness and cost-effectiveness of immediate 
delivery after PPROM in near term gestation compared to expectant management. Pregnant
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women with preterm prelabour rupture of the membranes at a gestational age from 34+0 weeks 
until 37+0 weeks will be included in a multicentre prospective randomised controlled trial. We will 
compare early delivery with expectant monitoring.
The primary outcome of this study is neonatal sepsis. Secondary outcome measures are maternal 
morbidity (chorioamnionitis, puerperal sepsis) and neonatal disease, instrumental delivery rate, 
maternal quality of life, maternal preferences and costs. We anticipate that a reduction of neonatal 
infection from 7.5% to 2.5% after induction will outweigh an increase in RDS and additional costs 
due to admission of the child due to prematurity. Under these assumptions, we aim to randomly 
allocate 520 women to two groups of 260 women each. Analysis will be by intention to treat. 
Additionally a cost-effectiveness analysis will be performed to evaluate if the cost related to early 
delivery will outweigh those of expectant management. Long term outcomes will be evaluated using 
modelling.
Discussion: This trial will provide evidence as to whether induction of labour after preterm 
prelabour rupture of membranes is an effective and cost-effective strategy to reduce the risk of 
neonatal sepsis.
Controlled clinical trial register: ISRCTN293I3500
Background
Preterm prelabour rupture of the membranes (PPROM) is 
an im portant clinical problem and a dilemma for the 
gynaecologist. On the one hand, awaiting spontaneous 
labour may lead to an increase in infectious disease for 
both m other and child, whereas on the other hand induc­
tion of labour leads to preterm birth with an increase in 
neonatal morbidity (e.g., respiratory distress syndrome 
(RDS)) and a possible rise in the number of instrumental 
deliveries.
The estimated incidence of PPROM between 34 and 37 
weeks of gestation is 1.5%, which equals about 3.000 
cases per year in the Netherlands. The incidence of RDS is 
estimated to decrease from 15% at 34 weeks to below 1% 
at 37 weeks' gestation [1]. On the other hand, the proba­
bility that sepsis occurs increases when expectant manage­
m ent is advocated. In case the child is born immediately 
after PPROM, the risk of sepsis is 2.5%, whereas it 
increases to 7.5% in case of expectant management [2,3].
Until now, management of PPROM between 34 and 37 
weeks' gestation varies in the Netherlands. In the guide­
line of the Dutch Society of Obstetrics and Gynaecology 
(NVOG) expectant management is advocated if the gesta­
tional age is under 35 weeks [4]. Beyond 35 weeks, the 
guideline makes no clear recommendation, and the deci­
sion for either induction of labour or expectant manage­
m ent (either in hospital or with monitoring at home), is 
left to local protocols. International guidelines do not 
make a clear statement either [5,6].
This dilemma can be explained by a lack of good clinical 
evidence. As a consequence, the course of action on this 
subject varies in the Netherlands. Data from the Dutch
National Delivery Registration indicate that in about 70% 
of the patients an expectant management has been prac­
tised, whereas in about 30% of the cases labour was 
induced preterm. The current national registrations pro­
vide no insight in the reason for induction in the latter 
group, as some inductions might have been performed 
following signs of intra-uterine infection.
In view of the lack of good clinical evidence and the prac­
tice variation described above, a randomised clinical trial 
comparing induction of labour and expectant monitoring 
in patients with PPROM is needed urgently.
We are aware of four small studies that have been per­
formed to discern between the treatment policies for 
PPROM [7-10]. Naef et al. compared induction of labour 
versus expectant management in a group of 120 patients 
with PPROM occurring at 34 until 37 weeks gestation and 
found a non-significant decrease of chorioamnionitis in 
the induction group without a significant difference in 
neonatal morbidity (including RDS) between both 
groups [7]. Patients with PPROM managed expectantly 
were hospitalised significantly longer. More babies of the 
expectant group were diagnosed with sepsis and admitted 
to the neonatal ward for a longer duration. This difference 
did not reach the level of significance due to the small 
num ber of the study.
Cox et al. compared maternal and neonatal outcome in a 
group of 129 patients with PPROM occurring at 30 until 
34 weeks' gestation after randomization between expect­
ant management and induction of labour [8]. Again, no 
significant differences in neonatal outcome were noted. 
However, a non-significant decrease in sepsis was seen in 
the induction group. Also, chorioamnionitis was
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observed less frequently in the latter group. Mercer et al. 
performed a similar study of 93 patients with PPROM in 
a different age category (32 until 36 weeks' gestation) and 
observed similar differences as Cox and co-workers [9].
Spinnato et al. found no difference in neonatal outcome 
between expected management and prom pt delivery in 47 
patients with premature rupture of membranes (before 36 
weeks) with documented foetal pulmonary maturity [10]. 
However, they demonstrated an increased risk of maternal 
infection when expectant management was applied.
These studies show a trend towards better neonatal out­
come in the induction group, bu t in these small samples 
differences were no t statistically significant. Even meta­
analysis did no t generate sufficient statistical power [11]. 
In view of the practice variation described above and the 
lack of sound clinical evidence for this clinical dilemma, 
we have recently started a multicentre trial.
Methods/Design
Aims
The aim of this study is to systematically compare early 
initiation of delivery and expectant management in case 
of preterm prelabour rupture of membranes in terms of 
neonatal sepsis and RDS, maternal health, health-related 
quality-of-life and costs. As it is impossible to blind the 
healthcare workers and patients involved for the strategy 
of allocation, we will use a multicentre randomised con­
trolled open label trial to assess the effects of initiation of 
delivery or expectant management on neonatal outcome. 
This study is set in the Dutch Obstetric Consortium, a col­
laboration of obstetric clinics in the Netherlands. Approx­
imately 40 clinics, including academic hospitals, non­
academic teaching hospitals and non-teaching hospitals 
will participate in this trial.
Participants/eligibility criteria
Women presenting with preterm prelabour rupture of the 
foetal membranes between 34+0 and 37+0 weeks' gestation 
who have not delivered within 24 hours after rupture of 
the foetal membranes are eligible for participation in the 
PPROMEXIL-trial. Even so women presenting with pre­
term prelabour rupture of foetal membranes after 26+0 
weeks gestation who have not delivered at 34+0 weeks of 
gestation are eligible for participation. Both women with 
singleton and women with multiple gestations can be 
included. Women with a child in breech presentation can 
also be included, and both an elective caesarean section 
and a vaginal delivery are allowed for these women.
Women with monochorionic multiple pregnancies, 
abnormal (non-reassuring) cardiotocogram (CTG), 
meconium stained amniotic fluid, signs of intrauterine 
infection, major foetal anomalies, labour, HELLP syn­
drome or severe pre-eclampsia, will no t be included in the 
study.
Procedures, recruitment, randomisation and collection o f  
baseline data
The research nurse and/or the staff of participating hospi­
tals will identify eligible women. After the subject has 
given informed consent for participation in the study, she 
will be randomised to either a policy that aims at termina­
tion of the pregnancy (intervention group) or a policy that 
aims at expectant management for spontaneous delivery 
(expectant group). Once the subject data have been 
entered anonymously in a web-based database, either a 
staff member or the research nurse will randomise using 
an internet based procedure. Randomisation will be 1:1 
for intervention or expectant management and stratified 
for centre and previous delivery.
At study entry baseline demographics, past obstetric and 
medical history will be recorded. Maternal temperature is 
measured and baseline blood samples are taken. From all 
participating women a vaginal swab is collected either at 
admission to the hospital with premature ruptured m em ­
branes or at study entry. Antibiotics are given in accord­
ance to local policy. All women will undergo an 
ultrasound examination at study entry. If a previous ultra­
sound examination was done within a fortnight before 
study entry in the same hospital, which revealed no 
abnormal results, these outcomes may be recorded at 
study entry. Women fill out a baseline quality of life ques­
tionnaire containing EuroQoL, 5D3L, HADS, SF-36 and 
background questions. They are also asked on their prior 
intervention preference.
At local centres data-collection will be the responsibility 
of the local research coordinator and the regional research 
nurses. The data for this study m ust be collected, coded 
and processed with adequate precautions to ensure 
patient confidentially.
Interventions
Intervention group
Women randomised for intervention will be planned for 
induction of labour or elective caesarean section as soon 
as reasonable after randomisation. Because of the fact that 
randomisation will take place preferable 24 hours after 
rupture of the foetal membranes it is imaginable that due 
to logistic reasons induction of labour is postponed until 
the following morning, but within 12 hours after ran­
domisation. Induction of labour will take place according 
to local policy. In case of breech presentation, a primary 
caesarean section is allowed based on the preference of 
both the patient and the gynaecologist. Similarly in case 
of a dichorionic twin an elective caesarean section may be
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performed because of the position of the presentation of 
the first twin.
Expectant group
Women randomised for expectant management will be 
treated according to local policy. This might be either in 
an outpatient or inpatient setting. If a patient in the 
expectant group reaches 37+0 weeks of gestation age, 
induction of labour is performed according to local pol­
icy. Whenever a patient with an indication for elective cae­
sarean section will be allocated to expectant management 
the caesarean section will be performed as soon as labour 
commences.
Follow up o f women and infants
Information is obtained on the condition, weight, length 
and neonatal morbidity and mortality from the infant and 
maternal records as well as maternal complications and 
length of stay. If applicable, neonatal antibiotic treatment, 
blood samples and cultures are recorded. In case of admit­
tance of the baby to the neonatal intensive care, high care 
or medium care unit, details of this admittance are also 
documented. The placenta will be sent for histological 
examination on chorioamnionitis and funisitis.
Six weeks and six months post partum neonatal length, 
weight, neurological disabilities, physical disabilities and 
maternal disabilities will be recorded. Patients will be 
asked to fill out follow-up quality of life questionnaires 
including EuroQoL, 5D3L, HADS, SF-36, SCL-90 also 
concerning the development of the child. W omen are also 
asked to (re)state their intervention preference. Long-term 
follow up of the children is not yet planned, and depends 
on future funding.
Outcome measures
The primary outcome measure is neonatal sepsis. Neona­
tal sepsis is defined as a positive blood culture, biochem­
ical infection parameters (C-reactive protein (CRP) above 
20 mg/l) or clinical signs of infection (apnoea, fever, 
intolerance for feeding, respiratory distress and/or 
haemodynamic instability) with positive surface cultures. 
An independent panel of paediatricians will define 
between proven or probable sepsis without knowledge of 
the outcome data.
Secondary infant outcome measures are respiratory dis­
tress syndrome (RDS) (defined according to the Organ 
dysfunction criteria), transient tachypnoea of the new­
born asphyxia (defined according to Sarnat), pneum otho­
rax/pneumomediastinum, late onset sepsis, 
hypoglycaemia, meconium aspiration syndrome, necro­
tizing enterocolitis (NEC) (defined according to Bell stag­
ing), hyperbilirubinemia, in, traventricular haemorrhage, 
periventricular leucomalacia, convulsions, other neuro­
logical abnormalities and congenital abnormalities [12­
14].
Secondary maternal outcome measures are ante partum 
haemorrhage, umbilical cord prolapse, signs of chorioam- 
nionitis (defined as fever before or during labour as a tem­
perature greater than 37,5°C on two occasion more than 
one hour apart or a temperature > 38,0°C with either uter­
ine tenderness (or contractions), leucocytosis, maternal or 
foetal tachycardia, or a foul-smelling vaginal discharge in 
absence of any other cause of hyperpyrexia), maternal 
sepsis (defined as temperature > 38.5 °C and positive 
blood culture or circulatory instability requiring intensive 
care monitoring), thrombo-embolic complications, uri­
nary tract infection treated with antibiotics, signs of 
endometritis (defined as temperature of > 38,0 °C on 2 
occasions at least one our apart after the first 24 h  post­
partum with associated uterine tenderness [15]), pneu­
monia, anaphylactic shock, HELLP-syndrome and death, 
incidence of instrumental deliveries, maternal quality of 
life, maternal intervention preference and costs. [15]
Other outcomes are direct medical and non-medical costs 
generated by maternal and neonatal resource utilisation 
during admission and post-discharge follow-up until 6 
weeks after randomisation. The economic evaluation will 
integrate the primary clinical outcome and costs in a cost- 
effectiveness analysis.
Statistical analysis
Sam ple size
This trial is designed to demonstrate a 66% reduction of 
neonatal sepsis from 7.5% in women in the expectant 
group to 2.5% in women in the induction group. This 
requires a total sample size of 520 patients with 80 % 
power and a significance level of p = 0.05.
D ata analysis
Data analysis will be performed on an intention to treat 
basis and study baseline characteristics will be compared. 
The relative risks and 95% confidence intervals will be cal­
culated for the relevant outcome measures. The analysis 
will be stratified for centre and parity. Moreover, we will 
evaluate whether the relative benefits of induction of 
labour will be stronger in multiparous women and in 
women with a ripe cervix at baseline.
In case of continuous data in the secondary outcome 
group, t-tests will be used whereas chi-square tests will be 
used if data are categorical. In case of equivalence between 
outcomes, the analysis will be repeated on a par protocol 
basis. Quality of life as well as pain scores will be analysed 
using repeated measures analysis of variance. [16]
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Serious Adverse Events will be reported to an independ­
ent data safety monitoring committee. A formal interim 
analysis is not planned.
Ethical considerations
This study has been approved by the ethic committee of 
the University Hospital Maastricht (Ref. no. MEC 05­
240). A total of about 40 academic and non-academic 
hospitals have signed an intention form to participate in 
the trial, m ost of them have started the medical ethics 
committee approval procedure. Before a collaboration 
clinic may start with randomisation of patients the local 
ethical committee m ust have given their approval. The 
trial is registered in  the controlled clinical trial register 
under number: ISRCTN29313500 [17]
Confidentially and data security
Initials of participants as well as a local patient number 
are recorded in the electronic database. Linking names 
with patient's numbers can only be done in the local clin­
ics. Data will be collected using Oracle Clinical Remote 
Data Capture (RDC), which is a new generation of appli­
cation system that enables collection and cleanup of clin­
ical trial data using the Internet. For detailed information 
on Oracle RDC, please visit the page of Oracle RDC prod­
ucts. Each participating clinic receives a login name and 
password to get access to the web-secured database. The 
access is restricted to the database of the clinic to which 
the password and login name belongs. Full access to the 
entire database is restricted to some members of the 
research staff.
Discussion
Preterm prelabour rupture of membranes is still a clinical 
problem in obstetric practice. Between 34 and 37 weeks 
there is a lack of good clinical evidence. Induction of 
labour might reduce the risks of neonatal sepsis. On the 
other hand it might increase the incidence of instrumental 
deliveries and neonatal respiratory distress syndrome. 
This trial is designed to answer these questions in respect 
to neonatal and maternal outcomes and costs-effective- 
ness.
We are aware of two other studies on the subject that are 
running. In Canada, a trial has been started that compares 
induction of labour to expectant management in women 
with PPROM. [18] This trial aims to recruit 360 women 
(Safety and Efficacy Study of Intentional Delivery in 
Women With Preterm and Prelabour Rupture of the Mem­
branes, Lacaze N).
In St Leonards, Australia, a trial has been recently started 
similar to the trial that we have started (PPROMT -  Pre­
term Prelabour Rupture Of the Membranes close to Term)
[19]. This trial aims to recruit 1812 women and has been
announced in the journal [20]. The respective investigator 
groups, including ours, have planned an individual 
patient data meta-analysis after completion of the trials.
Competing interests
The author(s) declare that they have no competing inter­
ests.
Authors' contributions
DH drafted the manuscript; DH, BM, DB, and CW partic­
ipated in the design of the study; BO participated in the 
design of the statistical analysis. All authors discussed and 
fine tuned the final study design. All authors are partici­
pating in the acquisition of data. Finally all authors read, 
revised and approved the final manuscript.
Acknowledgements
This study is funded by Z onM W  (grant number 945-07-212). [21]
References
1. Lewis DF, Futayyeh S, Towers CV, Asrat T, Edwards MS, Brooks GG: 
P re te rm  de live ry  from  34 to  37 weeks o f  gestation: Is resp i­
ra to ry  d istress syndrom e a p rob lem ? Am J Obstet Gynecol 1996, 
1 74:525-528.
2. Neerhof MG, Cravello C, Haney EI, Siver RK: T im ing  o f labour 
induction  a fte r p rem atu re  rup tu re  o f  m em branes between 
32 and 36 weeks gestation. Am J Obstet Gynecol 1999, 
1 80:349-352.
3. Lieman JM, Brumfield CG, Carlo W: P re te rm  p rem atu re  rup tu re  
o f  m em branes: Is the re  an op tim a l gestationa l age fo r  de liv ­
ery? Obstet Gynecol 2005, 105:12-17.
4. N V O G  rich tlijn  no. 46; H e t  breken van de v liezen  v o o r  het 
begin van de baring; juni. 2002.
5. American College of Obstetricians and Gynecologists: P rem a tu re  
rup tu re  o f  m em branes. In ACOG Practice Bullitin 1 Washington 
DC: ACO G ; 1998.
6. Garite TJ: M anagem en t o f  p rem ature  rup tu re  o f  m em branes. 
Clin Perinatol 2001, 28:837-844.
7. Naef RW, A lbert A, Ross EL, W eber M, Martin RW, Morrison : P re ­
m atu re  rup tu re  o f  m em branes at 34 to  37 w eeks gestation: 
Aggressive  versus conservative m anagem ent. Am J Obstet 
Gynecol 1998, 178:126-130.
8. Cox SM, Leveno KJ: Intentiona l de live ry  versus expectan t m an­
agem ent w ith  p re te rm  p rem atu re  rup tu red  m em branes at 
30 -  34 w eeks gestation. Obstet Gynecol 1995, 86:875-879.
9. Mercer BM, Crocker LG, Boe NM, Sibai MB: Induction versus 
expectan t m anagem ent in p rem atu re  rup tu re  o f  the  m em ­
branes w ith  m atu re  am n io t ic  flu id a t 32 to  36 weeks: a rand­
om ized  tria l. Am J Obstet Gynecol 1993, 169:775-782.
10. Spinnato JA, Shaver DC, Bray EM, Lipshitz J: P re te rm  p rem ature  
rup tu re  o f the  m em branes w ith  fetal pu lm onary  m atu rity  
present: a p rospective  study. Obstet Gynecol 1987, 69:96-201.
11. Hartling L, Chari R, Friesen C, Vandermeer B, Lacaze-Masmonteil T: 
A  system atic rev iew  o f in ten tiona l de live ry  in w om en  w ith  
p re te rm  p re labo r rup tu re  o f  m em branes. J M atern Fetal Neo­
natal M ed  2006, 19:177-87.
12. Goldstein B, G iroir B, Randolph A: Internationa l Consensus C o n ­
fe rence on Ped ia tr ic  Sepis. Internationa l ped ia tr ic  sepsis 
consensus conference: D e fin itions  fo r  sepsis and organ dys­
function  in ped iatrics. Pediatr Crit Care M ed  2005, 6:2-8.
13. Sarnat HB, Sarnat HS: N eona ta l encepha lopathy  fo llow ing  fetal 
distress: A  c lin ica l and E E G  study. Arch Neurol 1976, 33:696-705.
14. Neu J: N ec ro t iz in g  en teroco lit is: the  search  fo r  a unifying 
pathogen ic theo ry  leading to  prevention . Pediatr Clin North Am  
1996, 43:409-432.
15. Lieman JM, Brumfield CG, Carlo W , Ramsey PS: P re te rm  p rem a­
tu re  rup tu re  o f m em branes: Is the re  an op tim a l gestational 
age fo r  delivery? Obstet Gynecol 2005, 105:12-17.
Page 5 of 6
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2007, 7:11 http://www.biomedcentral.eom/1471 -2393/7/11
16. Hays WL: Statistics 4th edition. New York: Holt, Rinehart and W in­
ston; 1998.
17. m R C T  -  P re te rm  P rem a tu re  Rup tu re  O f  M em branes 
betw een 34 and 37 weeks: E X p e c ta n t m anagem ent versus 
Induction o f  Lab ou r [http://www.controlled-trials.com/mrct/trial/ 
257003/PPRQMEXIL]
18. C lin ica l trial: Safety and Efficacy S tudy o f  Intentiona l D e liv ­
ery  in W o m e n  W ith  P re te rm  and P re lab ou r Rup tu re  o f  the 
M em branes [http://clinicaltrials.gov/ct/show/NCT00259519;jses 
sionid=5l l720C5DF99l49F8A22D293DBDF07lE?order=l]
19. m R C T  -  A  random ised  con tro lle d  tr ia l o f im m ed ia te  de liv­
ery  versus expectan t care  in w om en  w ith  rup tu red  m em ­
branes c lose to  te rm  [http://www.controlled-trials.com/mrct/ 
trial/228805/PPROMT]
20. Morris JM, Roberts CL, Crowther CA, Buchanan SL, Henderson- 
Smart Dj, Salkeld G: P ro to co l fo r the  im m ed ia te  de live ry  ve r­
sus expectan t care  o f  w om en  w ith  p re te rm  p re labou r rup ­
tu re  o f  the  m em branes c lose to  te rm  (P P R O M T )  T r ia l 
[ISRCTN44485060]. BMC Pregnancy Childbirth 2006, 6:9.
21. Z on M w -P ro je c ten p oo rt -  Induction o f labou r versus expect­
an t m anagem ent in w om en  w ith  p re te rm  p rem atu re  rup ­
tu re  o f  m em branes betw een  34 and 37 w eeks [http:// 
zonmw.collexis.net/projectsummary.asp?foreignid=945072l2]
Pre-publication history
The pre-publication history for this paper can be accessed 
here:
http://www.biomedc.entral.eom/1471-2393/7/11/prepub
Publish with BioMed Central and every 
scientist can read your work free of charge
BioMed Central will be the most significant development for
disseminating the results o f biomedical research in our lifetime.”
Sir Paul Nurse, Cancer Research UK 
You r research papers w ill be:
• available free of charge to  the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours — you keep the copyright
Su b m it yo u r m an uscrip t here :
http://www.biomedcentral.com /info/publishing_adv.asp oB io Medcentral
Page 6 of 6
(page number not for citation purposes)
